Speaker Profile
Ph.D., CEO & Co-Founder, Allelica Inc
Biography
Giordano Botta is the Co-Founder and CEO of Allelica Inc, where he drives the development and clinical implementation of multi-ancestry polygenic risk scores (PRS). Under his leadership, Allelica pioneered the first clinical multi-ancestry PRS test for Coronary Artery Disease (CAD), breast and prostate cancer, now used by leading healthcare systems. He focuses on cost-effectiveness analysis to ensure the long-term sustainability of PRS tests. Botta has overseen the creation of a software engine and the integration of genomic and clinical data from over one million individuals of diverse ancestries to develop and validate PRS. His primary interest is advancing the integration of PRS for CAD and common cancers into standard medical care, improving prevention and early intervention strategies.
Talk
Multi-Ancestry Polygenic Risk Score for Heart Attack Prevention
Heart attacks, the leading cause of death, are highly preventable, yet 30% occur in individuals without traditional risk factors. This talk presents care pathways using PRS to identify high-risk individuals invisible to the standard of care. A new method to enhance accuracy in risk assessment across ancestries, without relying on predefined labelling, will be discussed.
Clinical Dx Showcase:
Allelica Inc
Allelica specializes in multi-ancestry polygenic risk scores (PRS) to predict risk for common diseases. Its advanced diagnostics empower physicians and healthcare systems to reduce disease burden, supported by major publications, five patents and endorsements from key opinion leaders.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
